Hypothalamic magnocellular neurons express either one of the neurohypophysial hormones, vasopressin or oxytocin, along with different neuropeptides or neuromodulators. Axonal terminals of these neurons are generally accepted to release solely the two hormones but not others into the circulation. Here, we show that secretin, originally isolated from upper intestinal mucosal extract, is present throughout the hypothalamo-neurohypophysial axis and that it is released from the posterior pituitary under plasma hyperosmolality conditions. In the hypothalamus, it stimulates vasopressin expression and release. Considering these findings together with our previous findings that show a direct effect of secretin on renal water reabsorption, we propose here that secretin works at multiple levels in the hypothalamus, pituitary, and kidney to regulate water homeostasis. Findings presented here challenge previous understanding regarding the neurohypophysis and could provide new concepts in treating disorders related to osmoregulation.
T
he pituitary is essential for life. It consists of adenohypophysis and neurohypophysis and is responsible for the release of hormones that regulate all major body functions, including water homeostasis, blood pressure, growth, development, and reproduction. Currently, only two nonapeptide hormones, vasopressin (Vp) and oxytocin (Oxt), are widely accepted to be released from the neurohypophysis. The two peptides differ by a single amino acid substitution and are synthesized within the magnocellular neurosecretory cells in the paraventricular nucleus (PVN) and supraoptic nucleus (SON). Oxytocin is best known for its role in parturition and lactation, whereas Vp is critical to water conservation in the renal collecting ducts via translocation and expression of aquaporin-2 (AQP2). In addition to Vp, many studies have indicated the presence of Vpindependent mechanisms in the kidney. In isolated collecting duct segments, Jeon et al. (1) found that the highest plasma concentration of Vp (10 pM) under severe dehydration could increase osmotic water permeability to only 44% of the maximal value. Our group has shown recently that secretin (SCT), a hormone that modulates water and electrolyte transport in pancreatic ductal cells (2) , liver cholangiocytes (3, 4) , and epididymal epithelial cells (5) , is part of the Vp-independent mechanisms in regulating renal water reabsorption (6) . Because we observed changes in plasma SCT levels during chronic hyperosmolality and the presence of intense SCT-immunoreactivity (IR) signals in the posterior pituitary, the present study intended to investigate a putative role of SCT as a pituitary hormone in the hypothalamo-neurohypophysial system, a central integrative structure that regulates coordinated responses to perturbations in water balance and osmotic stability.
Results and Discussion

Secretin Induces Expression of the Immediate Early Gene c-fos in the
Vasopressinergic Neurons of the Hypothalamic PVN and SON. The concentrations of SCT and Vp were 122 Ϯ 6 and 142 Ϯ 35 ng/g of protein in the rat hypothalamus and 799 Ϯ 87 and 4,684 Ϯ 426 ng/g of protein in the rat pituitary. Consistent with previous findings that showed a high concentration of SCT in the neurointermediate lobe of pituitary (7), the current study revealed intense IR signals for both SCT and its receptor (SCTR) almost exclusively in the posterior lobe (Fig. 1A) , where they were distributed evenly throughout the neuronal fibers with SCT-IR enriched in Herring bodies and axonal terminals but not in pituicytes. In the hypothalamus, abundant SCT and SCTR were detected primarily in the PVN and SON by both in situ hybridization and immunohistochemical staining (Fig. 1B) . These findings are in agreement with previous studies showing distinct localization of SCT-IR to the PVN and SON and intercalated hypothalamic nuclei (8) and binding of 125 I-SCT to hypothalamic homogenate (9) . Additionally, SCT-IR was found throughout the hypothalamo-neurohypophysial tracts. Within SON, SCT and SCTR were found to be present in the magnocellular neurons (Ͼ20 m) and in the varicose or beaded fibers located in the ventral position of the nucleus, whereas within the PVN high proportions of large (Ͼ20 m) and small (Ͻ20 m) neurons were shown to express SCT and SCTR. The latter findings indicated that SCT and SCTR are expressed in both parvocellular and magnocellular subdivisions of the PVN.
To investigate the potential activity of SCT within the hypothalamus, the expression of the immediate early Fos protein, which is a well-established marker to identify activated neurons in the autonomous and central nervous system after chemical, mechanical, or sensory stimuli, was examined 1 h after intracerebroventricular (ICV) injection of SCT. Fig. 2A shows the effects of SCT on activating Fos-IR in the rat hypothalamus compared with that of the saline control. In control rats treated with isotonic saline, in agreement with Pirnik et al. (10) , Chang et al. (11) , and Kobelt et al. (12) , no Fos signal was found in neither the PVN nor the SON. In SCT-injected rats, however, Fos-IR was detected over the whole areas of the PVN and SON. The Fos signals were found only in the nuclei of certain magnocellular neurons in the PVN and SON, thereby suggesting a regulated and differential response to SCT among individual magnocellular cells.
SCT Induces Vp Gene Expression and Its Secretion from the Hypothalamo-Pituitary Axis.
To identify the downstream mechanism of SCT, double-immunofluorescent labeling of Fos with either Vp or Oxt was performed (Fig. 2B) . Up-regulation of Fos was observed in the cytoplasm of both Vp-and Oxt-expressing neurons, whereas Fos protein was detected only within the nuclei of vasopressinergic neurons but not in the nuclei of oxytocinergic neurons. Expression of this immediate early gene in magnocellular cells has been shown already to link various physiological stimulations to Vp gene expression (13) (14) (15) . Thus, we hypothesized that SCT could stimulate Vp expression via the cAMP/ protein kinase A (PKA)/Fos pathway. To test this hypothesis, ICV injection of SCT coupled to laser capture microdissection and real-time PCR (Fig. 2C ) was performed. The ICV-SCT markedly up-regulated Vp transcript levels in the PVN and SON (64.1 Ϯ 13.5-fold in PVN and 51.9 Ϯ 17.6-fold in SON) and to a lesser extent Oxt expression (5.9 Ϯ 1.9-fold in PVN and 1.7 Ϯ 0.5-fold in SON). Neurons residing in the PVN were found to be more responsive than those in the SON to SCT stimulation. We next tested whether SCT could modulate locally the release of Vp from and within the hypothalamo-neurohypophysial axis (Fig. 2D) . Our in vitro data indicated that Vp is spontaneously released from hypothalamic and pituitary explants (0.031 Ϯ 0.0005 and 0.967 Ϯ 0.041 ng/mL from hypothalamic and pituitary explants, respectively), and 100 nM SCT could increase markedly Vp release from the hypothalamic explants, reaching 0.131 Ϯ 0.02 ng/mL after 5 min of incubation (Fig. 2Di) . This effect was SCT-specific and PKA-dependent, because coincubation of the antagonist secretin (5-27) (1 M) or PKA inhibitor H89 (5 M) could reduce significantly the SCT-evoked Vp release. In in vivo studies, ICV administration of SCT (0.45 g) was able to increase Vp concentrations in blood samples collected from the right jugular vein (Fig. 2Dii) . The plasma Vp levels in SCTtreated rats reached 3.78-fold within 30 min compared with those at time 0 or before peptide injection. Note also that Vp levels of control animals remained relatively constant throughout the sampling period, indicating that the observed changes in Vp levels were not due to acute hypovolemia nor the experimental procedure. Because SCT could not induce Vp release from isolated pituitary (Fig. 2Diii) , SCT therefore should stimulate Vp release into the circulation via direct modulation of the activity of vasopressinergic neurons at the hypothalamus rather than at their axonal terminals in the neurohypophysis. Thus, the stimulatory effect of SCT on Vp release appears to require the integrity of the hypothalamo-neurohypophysial structure.
SCT Is a Neurosecretory Hormone Released from the Posterior Pitu-
itary into the Systemic Circulation in Response to Hyperosmolality. To extend our previous study showing the function of SCT in regulating water reabsorption in kidney tubules (6), we monitored changes in the expression of SCT and SCTR in response to an increase in plasma osmolality by dehydration (Fig. 3A) . The basal hypothalamic SCT and Vp mRNA levels in ad libitum animals were 1.42 Ϯ 0.13 and 8.34 Ϯ 0.27 fmol/hypothalamus, respectively. After 3 days of water deprivation, which should cause chronic hypovolemia (16, 17) , SCT and SCTR expression levels were elevated significantly in the hypothalamus and pituitary (SCT, 1.58 Ϯ 0.11-fold in hypothalamus and 3.74 Ϯ 1.05-fold in pituitary; SCTR, 1.95 Ϯ 0.20-fold in hypothalamus and 3.10 Ϯ 0.55-fold in pituitary). These data, together with SCT's effects in augmenting Vp synthesis and release ( Fig. 2 C  and D) , implicated the importance of SCT in contributing to a sustained elevation of Vp levels during extended periods of hyperosmolality or during dehydration.
Because we also observed changes in plasma SCT levels in mice under water deprivation (6), the effects of chronic hyperosmolality on plasma SCT levels in rats therefore were monitored. This was accomplished by subjecting rats to 4 days of restricted water access or 5 days of 0.9% saline consumption, both of which are well-established dehydration paradigms to promote persistent secretion of Vp (16) . In our study, the basal levels of SCT and Vp in plasma were 0.074 Ϯ 0.004 and 0.116 Ϯ 0.008 ng/mL, respectively. During chronic hyperosmolality, plasma SCT concentrations also were elevated, reaching 0.554 Ϯ 0.092 ng/mL on the fourth day of water restriction and 0.733 Ϯ 0.056 ng/mL on the fifth day of saline consumption (Fig. 3B) . Although our data do not exclude that changes in plasma SCT levels could be caused by stress inherent in the dehydration paradigms, we showed here that SCT is released from its source into the circulation in chronic hyperosmotic conditions.
All of the data presented in this work support the notion that SCT could be released from the neurohypophysis into peripheral circulation under various physiological conditions. We therefore used K ϩ (80 mM) as a depolarizing stimulus and measured in vitro release of SCT from pituitary explants. Similar to Vp, SCT also is released spontaneously from the pituitary explants, albeit its basal level is approximately one order of magnitude lower than that of Vp (Vp, 0.967 Ϯ 0.041 ng/mL; SCT, 0.142 Ϯ 0.011 ng/mL). Exposure of pituitary explants to 80 mM K ϩ significantly evoked SCT release (Fig. 3 Ci and Cii; 0.468 Ϯ 0.043 ng/mL; Ϸ3.29-fold vs. basal release), which was abolished in the presence of the sodium channel blocker TTX (0.76 Ϯ 0.03-fold vs. basal release), indicating that it is action-potential-dependent (Fig. 3Cii) . The release of SCT is also high-voltage-gated (HVA) calcium-channel-dependent since only cadmium (Cd 2ϩ , 1.28 Ϯ 0.11-fold vs. basal) but not nickel (Ni 2ϩ , 3.33 Ϯ 0.34-fold vs. basal) was able to block it. To characterize further the Ca 2ϩ channel subtypes (L-, N-, P-, or Q-type) that are involved in this process, specific HVA blockers were used (Fig. 3C2) . Application of R-type calcium channel blocker SNX-482 (30 nM) had no effect (3.29 Ϯ 0.1-fold vs. basal), showing that SCT release from the pituitary does not depend on the R-type HVA channel. However, significant inhibitions were observed in the presence of the P-type channel blocker -Agatoxin IVA (1.56 Ϯ 0.18-fold vs. basal, a 52.6% blockage, P Ͻ 0.01), the L-type channel blocker nicardipine (1.77 Ϯ 0.21-fold vs. basal, a 46.2% blockage, P Ͻ 0.01), and the N-type channel blocker -conotoxin GVIA (2.08 Ϯ 0.21-fold vs. basal, 36.8% blockage, P Ͻ 0.05). In summary, L-, N-, and P-type HVA channels are involved in the K ϩ -evoked secretin release from the rat pituitary.
After in vitro studies, we next sought to establish in vivo release of SCT from the pituitary by electrical stimulation of PVN followed by monitoring SCT concentrations from plasma samples collected from the jugular vein. As illustrated in Fig. 3D , we found that direct stimulation of the PVN with either a single ( Fig. 3Dii ; 0.1-ms pulses at 50 Hz for a duration of 10 s, 200 A) or repeated monopolar pulses ( Fig. 3Di ; 100-500 A, 0.1-ms pulses at 50 Hz, 10 s on, 10 s off, for 2 min) could evoke release of SCT into systemic circulation, when compared with control animals with no electrical stimulation. This release of SCT was observed only when the PVN area was stimulated but not in other positions (data not shown). Positions of the probe and the site of stimulation were confirmed by a marked increase in blood pressure upon stimulation (18) and by histological examination after the experiments. In summary, our data indicated that chronic hyperosmolality could lead to the release of SCT from the posterior pituitary into systemic circulation by activating magnocellular neurons in the PVN of the hypothalamus.
To confirm that SCT is a neurosecretory factor, plasma SCT levels were monitored in hypophysectomized rats before and after water deprivation. Plasma SCT levels were found to be unaltered in hypophysectomized rats under such conditions (0.073 Ϯ 0.002 and 0.083 Ϯ 0.024 ng/mL before and after 18 h water deprivation, respectively; P Ͼ 0.5; n ϭ 20), again indicating that the source of elevated SCT during chronic hyperosmolaltity was the pituitary. Taken together, these observations not just confirm the potential of secretin as a posterior pituitary hormone but also provide explanations to abnormalities underlying type D syndrome of inappropriate antidiuresis (SIADH). In these patients, Vp release and response are normal, although abnormal renal expression, translocation of AQP2, or both were found (19) . Secretin as a neurosecretory hormone from the posterior pituitary, therefore, could be the long-sought Vpindependent mechanism to solve the riddle that has puzzled clinicians and physiologists for decades. Finally, as a neurosecretory hormone released from the posterior pituitary, future studies of SCT should provide a new target for prevention or therapeutic intervention for disorders, particularly SIADH, of body water homeostasis.
Materials and Methods
ICV Cannulation and Drug Administration.
A 30-gauge stainless steel guide cannula was placed into the lateral ventricle as described in refs. 20 and 21. Effects of chronic hyperosmolality on daily plasma SCT levels. Tap water was available ad libitum to the control group, whereas restricted water access or 0.9% saline was given to the treatment group. Blood was withdrawn daily from the tail to prepare plasma for the measurement of SCT using a rat SCT enzyme immunoassay kit (n ϭ 6 -9). * , P Ͻ 0.05 and ** , P Ͻ 0. 
Table 1. Oligonucleotides used in this study
Animals were allowed to recover for 4 days before peptide injection. Rat SCT peptide was purchased from Bachem. Hypophysectomy. The anterior and posterior lobes of the pituitary were removed by suction using a parapharyngeal approach (23) . The aspirated anterior and posterior pituitaries were examined to confirm the completeness of hypophysectomy. For sham hypophysectomy, the same procedure was performed, except that the pituitary was not aspirated. The incision was closed with a suture, and analgesia was provided as needed based on clinical observations of pain or distress.
Electrical
Peptide Release Experiments. Immediately after decapitation, the hypothalamus and pituitary were dissected out quickly. Peptide release experiments were performed as described in ref. 24 . The concentration of the target peptide was measured using rat SCT and Vp enzyme immunoassay kits (Phoenix Pharmaceuticals).
In Situ Hybridization. Sense and antisense riboprobes for rat SCT and SCTR were generated from their respective partial cDNA clone containing pBlueScript KSϩ using a digoxigenin RNA labeling Kit (Roche Diagnostics). Coronal brain sections were rehydrated, treated with proteinase K, and then acetylated before incubation at 50°C for 1 h with prehybridization buffer (pH 7.5) containing 50% formamide, 0.6 M NaCl, 10 mM Tris⅐HCl, 1.3ϫ Denhardt's solution, 1 mM EDTA, 550 g/mL denatured salmon sperm DNA, and 50 g/mL yeast tRNA. Hybridization was conducted overnight at 50°C in the same buffer (except that salmon sperm DNA concentration was reduced to 60 g/mL) supplemented with 10 mM DTT, 10% dextran sulfate, and 600 pg of heat-denatured RNA riboprobes. Posthybridization treatment and incubation with anti-digoxigenin antibody conjugated to alkaline phosphatase (Roche Diagnostics) were conducted as described in ref. Laser Capture Microdissection. Eight-micrometer sections of frozen brain tissues were fixed in ice-cold methanol and then prestained with hematoxylin under RNase-free conditions for histological identification of the specific hypothalamic nucleus of interest. After complete dehydration, sections were microdissected using a Pixcell IIe laser capture microdissection system with an infrared diode laser (Arcturus) and high-sensitivity caps (CapSure LCM Caps).
RNA Extraction, First-Strand cDNA Synthesis, and Real-Time PCR. RNA extraction and first-strand cDNA synthesis were performed as described earlier in ref. 5 , whereas the expression levels of various genes were measured by real-time PCR using the SYBR Green PCR kit (Applied Biosystems) as described in ref. 6 .
Drugs.
The porcine SCT antagonist secretin-(5-27) was purchased from Bachem. The PKA inhibitor H89, sodium channel blocker TTX, Q-type calcium channel blocker -conotoxin MVIIC, and R-type calcium channel blocker SNX-482 were purchased from Alomone Labs. The polypeptide toxin for the N-type calcium channel, -conotoxin GVIA, was purchased from Tocris. The P-type calcium channel blocker -agatoxin IVA from Agelenopsis aperta used in this study was the synthetic version purchased from Calbiochem. All other chemicals and the L-type calcium channel blocker nicardipine used in the peptide release experiment were purchased from Sigma.
Statistical Analysis. For quantitative real-time PCR analysis, data are shown as the means Ϯ SEM from at least three independent experiments, each in triplicate. All data were analyzed by one-way ANOVA and followed by a Dunnett's test using the computer software PRISM (version 3.0; GraphPad).
